{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:47:05Z","timestamp":1784814425791,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Federal Ministry for Economic Affairs and Climate Action","award":["# 01MT21004A"],"award-info":[{"award-number":["# 01MT21004A"]}]},{"DOI":"10.13039\/501100022805","name":"Dieter Morszeck Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022805","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is a heterogeneous disease, impeding early detection and risk stratification. Liquid biopsies (LBx) enable minimally invasive tumor profiling, but circulating tumor-derived DNA (ctDNA) detection remains difficult, particularly in early-stage PCa. We developed a multimodal LBx approach combining genomic and epigenomic cell-free DNA (cfDNA) features in plasma and urine from newly diagnosed PCa patients to improve early characterization of PCa and risk stratification of aggressive disease. Plasma and urine samples from 55 localized PCa (lPCa) patients, 18 advanced PCa (aPCa) patients, and 36 cancer-free controls were subjected to low-coverage whole-genome sequencing and methylated DNA immunoprecipitation sequencing to assess fragmentation, chromosomal instability, and methylation in cfDNA. This complementary approach yielded a 45% ctDNA detection rate in newly diagnosed PCa. Major differences were observed between aPCa and controls, reflecting increasing signals with tumor progression. Epigenomic cfDNA features differentiated lPCa from aPCa, and ctDNA was detected in 46% of PCa patients with prostate-specific antigen &lt;10\u2009ng\/mL, suggesting potential for risk stratification. This study highlights the value of multimodal LBx approaches for early characterization of primary PCa and identification of aggressive disease at initial diagnosis. Integration into clinical workflows could complement diagnostics and support personalized decision-making tailored to patients\u2019 PCa risk profiles.<\/jats:p>","DOI":"10.1038\/s41698-026-01343-y","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:16:33Z","timestamp":1772471793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Anja Lisa","family":"Riediger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Eickelschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Janke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Janscho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lazareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Duensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Stegle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"S\u00fcltmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"G\u00f6rtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1343_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 18, 79\u201392 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1343_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse, A. et al. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"1343_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41585-021-00524-7","volume":"19","author":"A Ali","year":"2022","unstructured":"Ali, A. et al. Prostate zones and cancer: lost in transition? Nat. Rev. Urol. 19, 101\u2013115 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"1343_CR4","first-page":"238","volume":"213","author":"SV Carlsson","year":"2025","unstructured":"Carlsson, S. V., Carroll, P. R. & Hamdy, F. C. Reevaluating the definition of clinically significant prostate cancer as Grade Groups 2 to 5: an imperative for improved risk stratification. J. Urol. 213, 238\u2013241 (2025).","journal-title":"J. Urol."},{"key":"1343_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","volume":"80","author":"H van Poppel","year":"2021","unstructured":"van Poppel, H. et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021. Eur. Urol. 80, 703\u2013711 (2021).","journal-title":"Eur. Urol."},{"key":"1343_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046\u20131055 (2014).","journal-title":"Eur. Urol."},{"key":"1343_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.juro.2018.05.016","volume":"200","author":"A Aminsharifi","year":"2018","unstructured":"Aminsharifi, A. et al. Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by Race and Body Mass Index. J. Urol. 200, 758\u2013766 (2018).","journal-title":"J. Urol."},{"key":"1343_CR8","volume":"2013","author":"D Ilic","year":"2013","unstructured":"Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. Cochrane Database Syst. Rev. 2013, CD004720 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1343_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO Guideline Part II: considerations for a prostate biopsy. J. Urol. 210, 54\u201363 (2023).","journal-title":"J. Urol."},{"key":"1343_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","volume":"25","author":"L De Mattos-Arruda","year":"2014","unstructured":"De Mattos-Arruda, L. et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25, 1729\u20131735 (2014).","journal-title":"Ann. Oncol."},{"key":"1343_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9760","volume":"6","author":"M Murtaza","year":"2015","unstructured":"Murtaza, M. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760 (2015).","journal-title":"Nat. Commun."},{"key":"1343_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz Jr.","year":"2014","unstructured":"Diaz, L. A. Jr. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579\u2013586 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1343_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.eururo.2024.01.002","volume":"85","author":"B Pope","year":"2024","unstructured":"Pope, B. et al. Ultrasensitive detection of circulating tumour DNA enriches for patients with a greater risk of recurrence of clinically localised prostate cancer. Eur. Urol. 85, 407\u2013410 (2024).","journal-title":"Eur. Urol."},{"key":"1343_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00176","volume":"3","author":"ST Hennigan","year":"2019","unstructured":"Hennigan, S. T. et al. Low Abundance of circulating tumor DNA in localized prostate cancer. JCO Precis. Oncol. 3, 1\u201313 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1343_CR15","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.3390\/cancers13225615","volume":"13","author":"AK Angeles","year":"2021","unstructured":"Angeles, A. K. et al. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer. Cancers 13, 5615 (2021).","journal-title":"Cancers"},{"key":"1343_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccell.2019.09.003","volume":"36","author":"Y van der Pol","year":"2019","unstructured":"van der Pol, Y. & Mouliere, F. Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell 36, 350\u2013368 (2019).","journal-title":"Cancer Cell"},{"key":"1343_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-025-03348-0","volume":"44","author":"F Janke","year":"2025","unstructured":"Janke, F. et al. Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer. J. Exp. Clin. Cancer Res. 44, 87 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1343_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4921","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, eaat4921 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1343_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101349","volume":"5","author":"N Moldovan","year":"2024","unstructured":"Moldovan, N. et al. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis. Cell Rep. Med. 5, 101349 (2024).","journal-title":"Cell Rep. Med."},{"key":"1343_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-12-0041","volume":"2","author":"ST B\u00f6rno","year":"2012","unstructured":"B\u00f6rno, S. T. et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2, 1024\u20131035 (2012).","journal-title":"Cancer Discov."},{"key":"1343_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat. Commun. 13, 6467 (2022).","journal-title":"Nat. Commun."},{"key":"1343_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00723-8","volume":"12","author":"CG Smith","year":"2020","unstructured":"Smith, C. G. et al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med. 12, 23 (2020).","journal-title":"Genome Med."},{"key":"1343_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11\u201322 (2010).","journal-title":"Cancer Cell"},{"key":"1343_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0107-z","volume":"8","author":"D Chandrananda","year":"2015","unstructured":"Chandrananda, D., Thorne, N. P. & Bahlo, M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med. Genomics 8, 29 (2015).","journal-title":"BMC Med. Genomics"},{"key":"1343_CR25","doi-asserted-by":"publisher","first-page":"61ra91","DOI":"10.1126\/scitranslmed.3001720","volume":"2","author":"YMD Lo","year":"2010","unstructured":"Lo, Y. M. D. et al. Maternal Plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the Fetus. Sci. Transl. Med. 2, 61ra91 (2010).","journal-title":"Sci. Transl. Med."},{"key":"1343_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2217\/epi.09.33","volume":"1","author":"M Ehrlich","year":"2009","unstructured":"Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics 1, 239\u2013259 (2009).","journal-title":"Epigenomics"},{"key":"1343_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.04.009","volume":"166","author":"CE Massie","year":"2017","unstructured":"Massie, C. E., Mills, I. G. & Lynch, A. G. The importance of DNA methylation in prostate cancer development. J. Steroid Biochem. Mol. Biol. 166, 1\u201315 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1343_CR28","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/cancers13112652","volume":"13","author":"M Oshi","year":"2021","unstructured":"Oshi, M. et al. Urine as a source of liquid biopsy for cancer. Cancers 13, 2652 (2021).","journal-title":"Cancers"},{"key":"1343_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A., Church, M., Rothwell, D., Dive, C. & Cook, N. Circulating tumour DNA \u2014 looking beyond the blood. Nat. Rev. Clin. Oncol. 19, 600\u2013612 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1343_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000531195","volume":"101","author":"S Kar","year":"2023","unstructured":"Kar, S., Niharika, Roy, A. & Patra, S. K. Overexpression of SOX2 gene by histone modifications: SOX2 enhances human prostate and breast cancer progression by prevention of apoptosis and enhancing cell proliferation. Oncology 101, 591\u2013608 (2023).","journal-title":"Oncology"},{"key":"1343_CR31","doi-asserted-by":"publisher","first-page":"41890","DOI":"10.18632\/oncotarget.17462","volume":"8","author":"D Gentilini","year":"2017","unstructured":"Gentilini, D. et al. Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget 8, 41890\u201341902 (2017).","journal-title":"Oncotarget"},{"key":"1343_CR32","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1038\/onc.2017.226","volume":"36","author":"WY Chen","year":"2017","unstructured":"Chen, W. Y. et al. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. Oncogene 36, 6213\u20136224 (2017).","journal-title":"Oncogene"},{"key":"1343_CR33","doi-asserted-by":"publisher","first-page":"djx118","DOI":"10.1093\/jnci\/djx118","volume":"109","author":"AW Wyatt","year":"2017","unstructured":"Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl. Cancer Inst. 109, djx118 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"1343_CR34","doi-asserted-by":"publisher","unstructured":"Markus, H. et al. Analysis of recurrently protected genomic regions in cell-free DNA found in urine. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.aaz3088 (2021).","DOI":"10.1126\/scitranslmed.aaz3088"},{"key":"1343_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/clinchem\/hvaa325","volume":"67","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Jagged ends of urinary cell-free DNA: characterization and feasibility assessment in bladder cancer detection. Clin. Chem. 67, 621\u2013630 (2021).","journal-title":"Clin. Chem."},{"key":"1343_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01710-w","volume":"22","author":"P Stejskal","year":"2023","unstructured":"Stejskal, P. et al. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol. Cancer 22, 15 (2023).","journal-title":"Mol. Cancer"},{"key":"1343_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.879108","volume":"13","author":"SM Dermody","year":"2022","unstructured":"Dermody, S. M., Bhambhani, C., Swiecicki, P. L., Brenner, J. C. & Tewari, M. Trans-renal cell-free tumor DNA for urine-based liquid biopsy of cancer. Front. Genet. 13, 879108 (2022).","journal-title":"Front. Genet."},{"key":"1343_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.clinbiochem.2017.02.017","volume":"50","author":"THT Cheng","year":"2017","unstructured":"Cheng, T. H. T. et al. Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clin. Biochem. 50, 496\u2013501 (2017).","journal-title":"Clin. Biochem."},{"key":"1343_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1525-1578(10)60497-7","volume":"6","author":"YH Su","year":"2004","unstructured":"Su, Y. H. et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J. Mol. Diagn. 6, 101\u2013107 (2004).","journal-title":"J. Mol. Diagn."},{"key":"1343_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/15592294.2020.1712876","volume":"15","author":"R Silva","year":"2020","unstructured":"Silva, R. et al. Evaluating liquid biopsies for methylomic profiling of prostate cancer. Epigenetics 15, 715\u2013727 (2020).","journal-title":"Epigenetics"},{"key":"1343_CR41","doi-asserted-by":"publisher","first-page":"759791","DOI":"10.3389\/fonc.2022.759791","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer. Front. Oncol. 12, 759791 (2022).","journal-title":"Front. Oncol."},{"key":"1343_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23445-w","volume":"12","author":"P Peneder","year":"2021","unstructured":"Peneder, P. et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nat. Commun. 12, 3230 (2021).","journal-title":"Nat. Commun."},{"key":"1343_CR43","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","volume":"27","author":"JM Burgener","year":"2021","unstructured":"Burgener, J. M. et al. Tumor-naive multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin. Cancer Res. 27, 4230\u20134244 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1343_CR44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1373\/clinchem.2018.301341","volume":"65","author":"THT Cheng","year":"2019","unstructured":"Cheng, T. H. T. et al. Noninvasive detection of bladder cancer by shallow-depth genome-wide bisulfite sequencing of urinary cell-free DNA for methylation and copy number profiling. Clin. Chem. 65, 927\u2013936 (2019).","journal-title":"Clin. Chem."},{"key":"1343_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.20967","volume":"69","author":"SR Payne","year":"2009","unstructured":"Payne, S. R. et al. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 69, 1257\u20131269 (2009).","journal-title":"Prostate"},{"key":"1343_CR46","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein, E. A. et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 32, 1167\u20131177 (2021).","journal-title":"Ann. Oncol."},{"key":"1343_CR47","doi-asserted-by":"publisher","first-page":"110330","DOI":"10.1016\/j.isci.2024.110330","volume":"27","author":"E Lleshi","year":"2024","unstructured":"Lleshi, E. et al. Prostate cancer detection through unbiased capture of methylated cell-free DNA. iScience 27, 110330 (2024).","journal-title":"iScience"},{"key":"1343_CR48","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012881","volume":"13","author":"F Mouliere","year":"2021","unstructured":"Mouliere, F. et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol. Med. 13, e12881 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1343_CR49","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809323","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere, F. et al. Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Mol. Med. 10, e9323 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1343_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/gm434","volume":"5","author":"E Heitzer","year":"2013","unstructured":"Heitzer, E. et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5, 30 (2013).","journal-title":"Genome Med."},{"key":"1343_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48501-x","volume":"13","author":"C Alix-Panabi\u00e8res","year":"2023","unstructured":"Alix-Panabi\u00e8res, C., Marchetti, D. & Lang, J. E. Liquid biopsy: from concept to clinical application. Sci. Rep. 13, 21685 (2023).","journal-title":"Sci. Rep."},{"key":"1343_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/joim.13709","volume":"294","author":"A Edsj\u00f6","year":"2023","unstructured":"Edsj\u00f6, A. et al. Precision cancer medicine: Concepts, current practice, and future developments. J. Intern. Med. 294, 455\u2013481 (2023).","journal-title":"J. Intern. Med."},{"key":"1343_CR53","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","volume":"14","author":"SY Shen","year":"2019","unstructured":"Shen, S. Y., Burgener, J. M., Bratman, S. V. & De Carvalho, D. D. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat. Protoc. 14, 2749\u20132780 (2019).","journal-title":"Nat. Protoc."},{"key":"1343_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316\u2013319 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1343_CR55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1343_CR56","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","volume":"3","author":"F Chemi","year":"2022","unstructured":"Chemi, F. et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat. Cancer 3, 1260\u20131270 (2022).","journal-title":"Nat. Cancer"},{"key":"1343_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.585","volume":"2","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Exploring epigenomic datasets by ChIPseeker. Curr. Protoc. 2, e585 (2022).","journal-title":"Curr. Protoc."},{"key":"1343_CR58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1471-2105-11-237","volume":"11","author":"LJ Zhu","year":"2010","unstructured":"Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinform. 11, 237 (2010).","journal-title":"BMC Bioinform."},{"key":"1343_CR59","unstructured":"Kolde, R. pheatmap: Pretty Heatmaps. R package version 1.0.12 Available at: https:\/\/CRAN.R-project.org\/package=pheatmap (2018)."},{"key":"1343_CR60","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2020)."},{"key":"1343_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."},{"key":"1343_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1907-4","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death Dis. 10, 697 (2019).","journal-title":"Cell Death Dis."},{"key":"1343_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4571-7","volume":"18","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer. BMC Cancer 18, 659 (2018).","journal-title":"BMC Cancer"},{"key":"1343_CR64","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, New York, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"1343_CR65","doi-asserted-by":"crossref","unstructured":"Sievert, C. Interactive Web-Based Data Visualization With R, Plotly, And Shiny. (Chapman and Hall\/CRC, 2019).","DOI":"10.1201\/9780429447273"},{"key":"1343_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.32614\/RJ-2016-060","volume":"8","author":"Y Tang","year":"2016","unstructured":"Tang, Y., Horikoshi, M. & Li, W. ggfortify: Unified interface to visualize statistical results of popular R Packages. R. J. 8, 474\u2013485 (2016).","journal-title":"R. J."},{"key":"1343_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."},{"key":"1343_CR68","unstructured":"Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. TNM Classification of Malignant Tumours. 8th edn, 272 pp. (John Wiley & Sons, 2016)."},{"key":"1343_CR69","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969\u2013974 (1998).","journal-title":"JAMA"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01343-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:41Z","timestamp":1773770861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01343-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01343-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}